{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-107340","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.469213+00:00","generated_at":"2026-06-16T23:09:30.087112+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru sells ENTADFI assets to Blue Water Vaccines for $20M upfront + up to $80M milestones","bullets":["Asset purchase closed April 19, 2023; buyer paid $6M at closing, owes $4M in FY2023 and $10M in FY2024.","Potential milestone payments of $10M/$20M/$50M if annual net sales reach $100M/$200M/$500M.","Buyer assumed 6% royalty on ENTADFI sales and up to $22.5M in milestone obligations from Camargo agreement.","Veru sold substantially all ENTADFI assets, including IP, regulatory approvals, inventory, and contracts.","Deal shifts Veru's focus away from ENTADFI; milestone payments uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-107340","json":"https://secwatch.observer/filing/0001193125-23-107340.json","markdown":"https://secwatch.observer/filing/0001193125-23-107340.md","text":"https://secwatch.observer/filing/0001193125-23-107340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312523107340/0001193125-23-107340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312523107340/d473204d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:09:30.087112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1372bc0765a13a945fb679301a35cf1a5193c10","claim":"VERU INC. completed a disposition involving Blue Water Vaccines Inc. for $20.0 million (closed 2023-04-19).","evidence_excerpt":"purchased substantially all of the assets related to the Company’s ENTADFI ® business. The transaction closed on April 19, 2023. The purchase price for the transaction was $20.0 million, consisting of $6.0 million paid at closing, an additional $4.0 million the Purchaser is obligated to pay the Company in the Company’s fiscal year 2023 and an additional $10","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312523107340/0001193125-23-107340-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Blue Water Vaccines Inc."},{"label":"Consideration","value":"$20.0 million"},{"label":"Closing","value":"2023-04-19"}],"fact_type":"ma_transaction"},{"claim_id":"d80621ca353adaf6521f1f6083296a264a09ab41","claim":"VERU INC. entered into Asset Purchase Agreement with Blue Water Vaccines Inc. valued at $20.0 million purchase price: $6.0 million closing, $4.0 million fiscal 2023, $10 million fiscal 202 (effective 2023-04-19).","evidence_excerpt":"On April 19, 2023, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Blue Water Vaccines Inc. (the “Purchaser”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312523107340/0001193125-23-107340-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Blue Water Vaccines Inc."},{"label":"Value","value":"$20.0 million purchase price: $6.0 million closing, $4.0 million fiscal 2023, $10 million fiscal 202"},{"label":"Effective","value":"2023-04-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}